FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380024> ?p ?o ?g. }

• W4387380024 abstract "Abstract Disclosure: S. Yuksel: None. R. Lopez Fanas: None. D. Schwartz: None. V. Tabatabaie: None. S. Sachdev: None. Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a rare, aggressive lymphoproliferative disorder associated with human T-cell leukemia virus type 1 (HTLV-1), often presenting with severe refractory hypercalcemia. Here, we present a rare case of bisphosphonate-resistant ATLL-associated hypercalcemia successfully treated with denosumab (Dmab). Clinical Case: A 47-year-old woman from Jamaica presented with pruritic rash of left forearm and bilateral lower extremity (LE) pain for 6 weeks. Laboratory evaluation noted serum Ca of 16.2 mg/dL (n 9-11), PTH 12.5 pg/mL (n 16-65), PTHrP 24 pg/mL (n 11-20) and 25(OH)D 16 ng/mL (n 30-60). 1,25(OH)2D level was normal. Cr was 1.5 mg/dL (n 0.7-1.2). X-rays demonstrated punctate lytic lesions throughout LEs. The patient received IV fluids, calcitonin, pamidronate 60 mg IV, and ergocalciferol 50,000 IU. Corrected Ca (cCa) improved to 9.3 mg/dL. However, hypercalcemia recurred after 2 days. HTLV-1 serology was positive. Flow cytometry and bone marrow biopsy were consistent with ATLL. When Ca rose to 14.3 mg/dL, Dmab 60 mg SC was administered. Within 1 week, she developed asymptomatic hypocalcemia with cCa of 7.1 mg/dL requiring oral calcium citrate and calcitriol. Stable normocalcemia was achieved after 10 days. Hospital course was complicated by pathologic right wrist fracture. Palliative radiation to LE was initiated. She was discharged on calcium citrate 2850 mg TID, calcitriol 0.25 mcg BID and ergocalciferol 50,000 IU weekly. The patient was treated with 6 cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab, as well as intrathecal methotrexate for CNS prophylaxis. She received 120 mg of Dmab 6 months after the first dose. Ca remained stable. Conclusion: ATLL-associated hypercalcemia is mediated by increased secretion of PTHrP, and RANK ligand and proinflammatory cytokines that promote RANK expression. Dmab is an effective treatment for ATLL-associated hypercalcemia as it specifically targets RANK ligand. A dose of 120 mg Dmab is recommended for patients with bisphosphonate-resistant hypercalcemia of malignancy and GFR greater than 30 mL/min. In another published case report on the use of Dmab in ATLL-associated hypercalcemia, treatment with Dmab 120 mg SC resulted in protracted hypocalcemia lasting 5 months despite calcium carbonate and Vitamin D supplements (1). Our patient had a significantly shorter hypocalcemia course likely due to reduced Dmab dose and more aggressive proactive treatment with ergocalciferol, calcium citrate and calcitriol. This case supports the successful use of Dmab in bisphosphonate-resistant ATLL-associated hypercalcemia. Protracted Dmab-induced hypocalcemia may be mitigated by Dmab dose reduction even in the presence of normal GFR and early aggressive treatment with calcium citrate and calcitriol. Reference: (1) Japp et al. AACE Clin Case Rep.2019;5:e210-213 Presentation: Saturday, June 17, 2023" @default.
• W4387380024 created "2023-10-06" @default.
• W4387380024 creator A5015957877 @default.
• W4387380024 creator A5018933077 @default.
• W4387380024 creator A5024595158 @default.
• W4387380024 creator A5052166635 @default.
• W4387380024 creator A5093011331 @default.
• W4387380024 date "2023-10-01" @default.
• W4387380024 modified "2023-10-16" @default.
• W4387380024 title "SAT258 Successful Treatment Of Adult T-cell Leukemia-lymphoma Induced Hypercalcemia With Denosumab" @default.
• W4387380024 doi "https://doi.org/10.1210/jendso/bvad114.554" @default.
• W4387380024 hasPublicationYear "2023" @default.
• W4387380024 type Work @default.
• W4387380024 citedByCount "0" @default.
• W4387380024 crossrefType "journal-article" @default.
• W4387380024 hasAuthorship W4387380024A5015957877 @default.
• W4387380024 hasAuthorship W4387380024A5018933077 @default.
• W4387380024 hasAuthorship W4387380024A5024595158 @default.
• W4387380024 hasAuthorship W4387380024A5052166635 @default.
• W4387380024 hasAuthorship W4387380024A5093011331 @default.
• W4387380024 hasBestOaLocation W43873800241 @default.
• W4387380024 hasConcept C124490489 @default.
• W4387380024 hasConcept C126322002 @default.
• W4387380024 hasConcept C2776079296 @default.
• W4387380024 hasConcept C2776286101 @default.
• W4387380024 hasConcept C2776541429 @default.
• W4387380024 hasConcept C2776694085 @default.
• W4387380024 hasConcept C2778461978 @default.
• W4387380024 hasConcept C2778496288 @default.
• W4387380024 hasConcept C2778570526 @default.
• W4387380024 hasConcept C2779627488 @default.
• W4387380024 hasConcept C71924100 @default.
• W4387380024 hasConcept C90924648 @default.
• W4387380024 hasConceptScore W4387380024C124490489 @default.
• W4387380024 hasConceptScore W4387380024C126322002 @default.
• W4387380024 hasConceptScore W4387380024C2776079296 @default.
• W4387380024 hasConceptScore W4387380024C2776286101 @default.
• W4387380024 hasConceptScore W4387380024C2776541429 @default.
• W4387380024 hasConceptScore W4387380024C2776694085 @default.
• W4387380024 hasConceptScore W4387380024C2778461978 @default.
• W4387380024 hasConceptScore W4387380024C2778496288 @default.
• W4387380024 hasConceptScore W4387380024C2778570526 @default.
• W4387380024 hasConceptScore W4387380024C2779627488 @default.
• W4387380024 hasConceptScore W4387380024C71924100 @default.
• W4387380024 hasConceptScore W4387380024C90924648 @default.
• W4387380024 hasIssue "Supplement_1" @default.
• W4387380024 hasLocation W43873800241 @default.
• W4387380024 hasOpenAccess W4387380024 @default.
• W4387380024 hasPrimaryLocation W43873800241 @default.
• W4387380024 hasRelatedWork W1996943007 @default.
• W4387380024 hasRelatedWork W2018830831 @default.
• W4387380024 hasRelatedWork W2065962239 @default.
• W4387380024 hasRelatedWork W2508842317 @default.
• W4387380024 hasRelatedWork W2943676592 @default.
• W4387380024 hasRelatedWork W3017270174 @default.
• W4387380024 hasRelatedWork W3028887354 @default.
• W4387380024 hasRelatedWork W4248326559 @default.
• W4387380024 hasRelatedWork W1907135228 @default.
• W4387380024 hasRelatedWork W2037377379 @default.
• W4387380024 hasVolume "7" @default.
• W4387380024 isParatext "false" @default.
• W4387380024 isRetracted "false" @default.
• W4387380024 workType "article" @default.